U.S. Markets closed

Axovant Sciences Gene Therapy Showing Progress, Pipeline Review

NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Axovant Sciences Ltd. (AXGT), a part of the Roivant family of companies, and is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases.

Gene therapy aims to address diseases at the most fundamental level: the genes that lead to the disease or its symptoms. There are several different approaches employed by gene therapy.

Our world class analyst has info on clinical milestones and much more here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/axgt/

The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), Parkinson's disease, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.

Company pipeline, recent developments and our analyst take on AXGT here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/axgt/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/539330/Axovant-Sciences-Gene-Therapy-Showing-Progress-Pipeline-Review